China A-share innovative drug stocks rally; Wanbang Pharma up over 10%

A broad-based move across innovative drug names without a cited catalyst suggests sector-level positioning rather than company-specific news, which makes the durability of the rally the open question. The breadth — from Wanbang's double-digit gain to smaller names like HitGen and Nearshore Protein — points to sentiment rotating into the theme rather than fundamentals repricing any single issuer. For a sector that trades heavily on policy and pipeline headlines, an unexplained pop is worth watching for whether follow-through appears or the move fades as quickly as it came.